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1. Introduction 
Normal insulin sensitivity is essential for the maintenance of normal circulating 
carbohydrate and lipid levels and their metabolism. In healthy individuals elevated blood 
glucose levels stimulate the pancreas to release insulin which lowers blood glucose levels by 
stimulating glucose uptake and metabolism in muscle, adipose tissue and several other 
insulin sensitive organs. Blood glucose increases are not only countered by increased tissue 
glucose uptake but also by insulin induced suppression of hepatic glycogenolysis and 
gluconeogenesis. Besides its effects on blood glucose, insulin also affects circulating lipid 
levels by reducing hepatic very low density lipoprotein cholesterol (VLDL-cholesterol) 
formation from free fatty acids (FFAs). This is primarily due to the reduced free fatty acid 
supply to the liver caused by insulin induced suppression of lipogenesis in adipose tissue 
[1]. In addition to its effects on lipogenesis, insulin also reduces lipolysis in adipose tissue by 
inhibiting hormone sensitive lipase. The latter hydrolyses adipocyte triglycerides to release 
free fatty acids and glycerol into the circulation. When delivered acutely, insulin inhibits 
fatty acid synthase while chronic hyperinsulinaemia (as occurs in insulin resistance) may 
induce fatty acid synthase activity and increase fatty acid synthesis [2]. The net effect of 
elevated insulin in normal healthy individuals is to reduce circulating glucose and free fatty 
acid levels.  
When an individual becomes insulin resistant, control of circulating lipid and blood glucose 
levels is compromised. Insulin resistance ensues when normal physiological concentrations 
of insulin are unable to induce effective uptake of glucose by insulin sensitive tissue. As a 
compensatory mechanism aimed at maintaining euglycaemia, pancreatic insulin secretion 
increases leading to a state of hyperinsulinaemia. If the elevated insulin levels are 
inadequate to fully compensate for the insulin insensitivity glucose intolerance ensues. The 
degree of glucose intolerance in insulin resistant individuals is thus dependent on the extent 
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of the loss of the in vivo function of insulin, and the ability of the pancreas to adjust for this 
by secreting more insulin [3, 4]. Once elevated circulating levels of insulin are no longer able 
to maintain euglycaemia, and glucose levels deviate beyond normal physiological ranges an 
individual is considered to be frankly diabetic.  
Myocardial insulin resistance translates to compromised intracellular insulin signalling and 
reduced glucose oxidation rates in animal models of obesity [5] and adversely affects 
myocardial mechanical function and tolerance to ischaemia and reperfusion. In this chapter 
we will review the mechanisms implicated in the aetiology of insulin resistance (skeletal and 
heart muscle) and discuss the effects of insulin resistance on cardiac metabolism, mechanical 
function and tolerance to ischaemia and reperfusion. We will also briefly review therapies 
used to prevent or counter insulin resistance and its associated adverse effects on the 
cardiovascular system. 
2. Myocardial insulin signalling 
Insulin induced activation of the insulin receptor (IR) invokes a cascade of events which 
ultimately enhances myocardial glucose uptake and metabolism. Insulin binding to its 
receptor results in autophosphorylation and activation of the insulin receptors (IRs) intrinsic 
tyrosine kinases. Following phosphorylation the insulin receptor phosphorylates insulin 
receptor substrate (IRS) [6] which subsequently associates with phosphoinositide 3-kinase 
(PI3K) via its p85 subunit [7, 8]. These events are vital for initiating insulin’s effects on glucose 
metabolism [6, 9, 10].  Activated PI3K will induce (via various signalling mechanisms) protein 
kinase B (PKB/Akt)[11] which plays a pivotal role in glucose metabolism by regulating the 
translocation of the cytosolic glucose transporter type 4 (GLUT4), to the sarcolemma [12, 13]. 
Inhibition of PI3K and/or PKB/Akt attenuates sarcolemmal GLUT4 translocation, effectively 
reducing insulin stimulated signalling and glucose uptake [14, 15].  Besides facilitating glucose 
uptake via GLUT4, insulin stimulation also increases glycolytic flux rates through activation of 
phosphofructosekinase 2 (PFK-2) which promotes the production of fructose-2,6-bisphosphate 
from fructose-6-phosphate [16-18]. Fructose-2,6-bisphosphate stimulates PFK-1 activity, which 
will also enhance glycolysis (see review by Hue et al. [18]). 
Although insulin increases long chain fatty acid (LCFA) uptake into the cardiomyocyte by 
increasing sarcolemmal fatty acid translocase/cluster of differentiation 36 (FAT/CD36) [19], 
elevated insulin levels also suppress tissue fatty acid β-oxidation rates. This suppression is 
most likely due to the effects of by-products of elevated glucose oxidation on malonyl-CoA 
levels [20]. As acetyl-CoA levels increase, acetyl-CoA carboxylase (ACC) is activated which 
increases malonyl-CoA induced inhibition of fatty acid oxidation. 
3. The role of obesity or a high fructose diet in the aetiology of insulin 
resistance 
Insulin resistance is strongly associated with both obesity and the consumption of high 
fructose containing diets [21-25]. Although not all obese individual are insulin resistant, 
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there is a strong association between obesity and insulin resistance [21, 25]. Adipose tissue is 
not only a storage organ but also a metabolically active organ synthesising and secreting a 
large range of substances that include fatty acids, pro-inflammatory cytokines, angiotensin 
II, leptin, resistin, visfatin and other adipocytokines [26] that can all influence tissue 
metabolism. Obesity and high fructose diets both induce increases in: 1) circulating FFAs 
[27, 28], 2) renin-angiotensin system (RAS) activity [29, 30], and 3) inflammation (caused by 
tissue and macrophage derived pro-inflammatory cytokines) [31] that are all associated 
with, and implicated in insulin resistance.  
Besides the negative impact of obesity on circulating lipids, recent studies provide 
convincing evidence for a role for high fructose diets in dyslipidaemia and insulin resistance 
[24, 27, 32]. These lipid profile altering effects of high fructose diets are primarily caused by 
fructose induced alterations in hepatic lipid metabolism [22-24]. Hepatic fructose 
metabolism differs significantly from glucose metabolism with fructose being a lipogenic 
sugar that promotes the deposition of triglycerides in adipose tissue and ectopic organs such 
as the liver and muscle. This tissue triglyceride accumulation eventually contributes to 
dyslipidaemia and insulin resistance [22, 27, 33]. 
Increasing dietary fructose consumption increases plasma triglyceride levels through 
stimulation of hepatic lipogenesis [34] and decreased VLDL-triglyceride removal from the 
plasma by adipose tissue [35]. Fructose evidently also activates genes involved in hepatic de 
novo lipogenesis [36, 37] which causes increased hepatic fatty acid generation. These fatty 
acids are incorporated into hepatic triglycerides which promotes VLDL-triglyceride 
synthesis and release from the liver (Figure 1)[38].  
A recent review highlights the possible effects of high fructose diets on hepatic insulin 
resistance [22]. These authors propose that high fructose diets promote hepatic 
inflammation by increasing fatty acid -oxidation (secondary to hepatic lipid accumulation) 
which generates peroxidation products that stimulate inhibitor of nuclear factor kappa-B 
kinase subunit beta (IKK) and activate nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFB). The NFB then enters the nucleus and induces the transcription of 
genes that encode for pro-inflammatory cytokines that include tumour necrosis factor alpha 
(TNF) and interleukin-6 (IL-6). These cytokines potentially activate c-Jun N-terminal 
kinase-1 (JNK-1) which will increase inhibitory serine307 phosphorylation of IRS-1 and 
contribute to hepatic insulin resistance [22] (Figure 2).  
Because of its lipogenic effects, fructose causes more marked changes in 24 hour lipid 
profiles than does the consumption of glucose while also favouring visceral rather than 
subcutaneous fat deposition [33]. This fat deposition pattern differs from that of glucose which 
promotes subcutaneous adipose tissue deposition rather that visceral fat deposition in men 
[39].  In rodents, a high fructose diet increases intrahepatic fat content and serum VLDL-
triglyceride concentrations within 6 weeks of feeding. In the same study intramuscular fat 
content was increased within 3 months of initiating the high fructose feeding with these 
changes being closely followed by hepatic and muscle insulin resistance [32]. Another animal 
based study supports a role for high fructose diets in increased hepatic VLDL-triglyceride 
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secretion [40]. In humans increasing fructose content in the diet increases plasma triglycerides 
[34, 41], decreases VLDL-triglyceride clearance [35] and increases triglyceride deposition in 
hepatocytes and skeletal muscle within a week of increasing dietary fructose content [41]. 
 
Figure 1. Mechanism for high fructose diet induced dyslipidaemia and ectopic lipid accumulation. 
High fructose diets promote hepatic de novo lipogenesis and lipid accumulation and reduce extra-
hepatic VLDL-triglyceride clearance.  The associated hypertriglyceridaemia promotes adipose tissue 
expansion (obesity) and muscle lipid accumulation which induces insulin resistance.  
Since high fructose diets are often also associated with obesity, it is difficult to differentiate 
between the effects of the changes in dietary fructose content and the effects of obesity on 
tissue insulin sensitivity. Data from studies demonstrating that some individuals are obese 
but metabolically healthy [42] and metabolic syndrome appears to be more closely linked to 
intrahepatic fat content than obesity per se [1, 41, 43], suggests that hepatic lipid metabolism 
and circulating lipid levels play a critical role in the induction of insulin resistance in 
response to obesity and high fructose diets. Tappy and co-workers [23, 24] recently 
proposed that fructose increases hepatic de novo lipogenesis which leads to intrahepatic lipid 
deposition, hepatic insulin resistance and increased VLDL-triglyceride secretion. This 
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potentially leads to increased visceral fat deposition while the elevated VLDL-triglyceride 
and inhibition of lipid oxidation (induced by fructose) may promote ectopic fat deposition 
in muscle with lipotoxicity leading to systemic insulin resistance (Figure 1) [22-24] 
 
Figure 2. The proposed mechanism for intrahepatic lipid accumulation induced stimulation of -
oxidation and ROS generation. ROS induced increases in cytokine (TNF and possibly other cytokines) 
expression and synthesis activates JNK which phosphorylates IRS-1 (insulin receptor substrate) at the 
serine307 residue. This inhibitory phosphorylation of IRS-1 prevents its tyrosine phosphorylation by the 
insulin receptor and interferes with the normal insulin signalling cascade (Illustration modified from 
review by Rutledge and Adeli [22]. 
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The experimental evidence implicating inflammation/pro-inflammatory cytokines and 
overactive renin-angiotensin systems (organ and systemic) in the aetiology of insulin 
resistance will be discussed later. We will first review the evidence for a role for elevated 
circulating free fatty acids, and tissue triglycerides and lipid intermediates accumulation in 
the aetiology of insulin resistance in skeletal and heart muscle. 
4. The role of free fatty acids and intracellular lipid accumulation in 
insulin resistance 
A prevalent metabolic change associated with obesity [44-49] and high fructose feeding [22-
24] is the increase in the circulating free fatty acids and triglycerides. Under conditions of 
over-nutrition and dyslipidaemia, not all fatty acids entering the cell are utilized for 
oxidative purposes. Long chain fatty acyl-CoA accumulation provides substrates for non-
oxidative processes such as triglyceride, diacylglycerol (DAG) and ceramide synthesis [50, 
51]. In the myocardium lipid accumulation is a direct result of a mismatch between fatty 
acid uptake and oxidation by the cell [47, 52]. What is not clear is whether this accumulation 
is due to: 1) increased FFA uptake by the heart 2) compromised FFA oxidation, or, 3) a 
combination of the two.  
There is a strong link between increased circulating free fatty acids, myocardial triglyceride 
accumulation and insulin resistance. Increased circulating free fatty acids increase the 
expression of sarcolemmal fatty acid transporters and increases fatty acid uptake into the 
myocyte. Obese Zucker rats [46, 48] and db/db mice [53] with insulin resistance have 
increased FAT/CD36 localised to the sarcolemma. The exact mechanism for the increased 
localisation of FAT/CD36 in the sarcolemma is not clear but may relate to the chronic 
hyperinsulinaemia associated with insulin resistance. It is well established that insulin 
stimulates FAT/CD36 translocation to the sarcolemma [54, 55]. This increased sarcolemmal 
FAT/CD36 content increases fatty acid uptake in cardiac myocytes and possibly leads to 
tissue fatty acyl-CoA accumulation if not metabolised through concomitant increased -
oxidation [56].  Besides its adverse effects on insulin signalling and glucose metabolism, 
excessive intramyocellular lipid accumulation may also have direct lipotoxic effects [50, 57]. 
Both altered substrate utilization and excess intramyocardial lipid accumulation which is 
characteristic of obesity, dyslipidaemia and insulin resistance may have serious cardiac 
consequences that ultimately lead to compromised cardiac metabolism, morphology and 
mechanical function.  
Lipid intermediates may adversely influence insulin signalling and contribute to insulin 
resistance [5, 58, 59]. The accumulation of triglycerides, diacylglycerol (DAG) and ceramide 
is known to activate kinases that down-regulate insulin signalling [60-62]. These kinases 
include JNK, IKK and protein kinase C (PKC) that is known to inhibit insulin signalling via 
serine phosphorylation of IRS-1 [5, 63]. 
Ceramide accumulation occurs through de novo synthesis from saturated fatty acids [64] or 
hydrolysis of sphingomyelin [65]. It has been shown to cause insulin resistance by inhibiting 
Akt phosphorylation in skeletal muscle [66-68] and adipocytes [69] with the 
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pharmacological inhibition of ceramide synthesis being effective in preventing lipid induced 
insulin resistance in rats [67, 70]. 
Models of lipotoxicity have also demonstrated that elevated myocardial ceramide levels are 
associated with increases in indices of apoptosis [52, 71]. Rat neonatal cardiomyocytes 
incubated with physiological concentrations of palmitate have increased intracellular 
triglycerides, increased ceramide levels and increased indices of apoptosis [72]. The 
mechanism implicated in ceramide induced apoptosis may involve activation of NFκB 
which in turn up regulates inducible nitric oxide synthase (iNOS) expression [73]. The 
resulting increase in nitric oxide production [74] may cause a subsequent rise in the 
formation of peroxynitrite, which induces mitochondrial cytochrome C release [75] and 
subsequent apoptosis. In addition, ceramide has been shown to directly induce the 
generation of damaging reactive oxygen species in the mitochondria [76]. Obese insulin 
resistant (prediabetic) Zucker rats also have elevated intramyocardial triglycerides which 
are accompanied by increased myocardial ceramide levels and cardiomyocyte apoptosis. 
These cellular alterations are present before the onset of diabetes and cardiac dysfunction 
[71]. Reducing myocardial lipid levels by treating the rats with peroxisome proliferator-
activated receptor gamma (PPAR) agonists lead to reduced cardiac ceramide levels and 
apoptosis and prevented cardiac dysfunction [71]. In a similar study, mice over-expressing 
cardiac specific long chain acyl-CoA synthase display high intramyocardial triglycerides 
and ceramide levels. These changes were accompanied by increased DNA fragmentation 
and cytochrome C release with the mice developing cardiac hypertrophy and left-
ventricular dysfunction [52]. 
Lipid infusion increases intracellular DAG and causes skeletal muscle insulin resistance in 
rodents [60]. This association between intracellular DAG levels and skeletal muscle insulin 
resistance has been confirmed in several rodent and human studies [77-79]. Increased 
muscle DAG is associated with increased activation of protein kinase C theta (PKC-) in 
obese and diabetic patients [80, 81]. Increased PKC- activation interferes with insulin 
signalling by increasing IRS-1 serine307 phosphorylation (Figure 3)[60, 81]. Accelerating fatty 
acid oxidation rates potentially prevents fatty acid, acetyl-CoA and subsequent DAG 
accumulation and may improve insulin sensitivity. This proposal was recently supported by 
a study showing that carnitine palmitoyltransferase I (CPT-1) over-expression in L6E9 
myotubes increases mitochondrial fatty acid uptake, decreased intracellular DAG 
concentrations and protects against elevated fatty acid induced insulin resistance [82]. 
4.1. Evidence for lipid accumulation in skeletal muscle insulin resistance  
An inverse correlation exists between intramuscular lipid content and insulin sensitivity. 
Measurements of insulin sensitivity (120 min euglycaemic hyperinsulinaemic clamp) in 
skeletal muscle from healthy subjects demonstrated that high intramuscular lipid content 
was associated with lower whole body insulin stimulated glucose uptake. These subjects 
also exhibited elevated circulating free fatty acids, reduced tyrosine phosphorylation of the 
insulin receptor (IR) and lower (insulin receptor substrate) IRS-1 mediated PI3K activation 
during hyperinsulinaemia than subjects with low intramuscular lipids [83]. Studies 
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comparing lean and obese individuals have made similar observations linking intracellular 
lipid accumulation to skeletal muscle insulin resistance [84, 85]. Boden and colleagues [86] 
reported a strong association between serum free fatty acid levels, intramuscular lipid 
content and insulin resistance after lipid injection in healthy subjects. Elevated circulating 
free fatty acid levels, induced by lipid injection, was associated with a gradual increase in 
intramuscular lipid content and a 40% increase in insulin resistance. These observations also 
corroborated earlier studies demonstrating that elevated fatty acids reduced skeletal muscle 
glucose uptake in humans [87]. 
 
Figure 3. The proposed mechanism for dyslipidaemia induced insulin resistance. Increased circulating 
free fatty acids as occurs during overfeeding/obesity and/or high fructose diet feeding will increase fatty 
acid uptake. Long chain acetyl CoA not oxidised can be used in non-oxidative pathways with the 
generation of triglycerides, diacylglycerol (DAG) and ceramide. Both the latter lipid metabolites have 
been implicated in aetiology of insulin resistance through the activation of PKC, IKK and JNK.  
In rodent skeletal muscle, experimentally elevated circulating free fatty acids increased 
intracellular acetyl-CoA and DAG levels which was coupled to increased active protein 
kinase C (PKC) theta. These changes were accompanied by increased IRS-1 serine 
phosphorylation, reduced IRS-1 tyrosine phosphorylation and reduced IRS-1 associated 
PI3K activity [60, 88]. Phosphorylation of IRS-1 at serine307 evidently hinders IRS-1’s 
interaction with PI3K and therefore interferes with normal insulin signalling. 
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4.2. Evidence for lipid accumulation in cardiac muscle insulin resistance  
Similar associations between increased intracellular lipid accumulation and reduced insulin 
sensitivity have been observed in cardiac muscle from obese insulin resistant animals [47, 
71, 89, 90]. In obese insulin resistant JCR:LA-cp rats, the increased supply of circulating free 
fatty acids was associated with a 50% increase in myocardial triglyceride content and a  50% 
reduction in myocardial glycolytic flux rates [89].  
In humans, plasma free fatty acid levels correlate with intramyocardial triglyceride levels 
[91]. This association is also evident in obese [91, 92], obese glucose intolerant [93] and 
diabetic [93, 94] individuals. Excessive intramyocardial triglyceride accumulation precedes 
the development of type-2 diabetes and tends to increase linearly with the degree of 
systemic insulin resistance [93]. Obese insulin resistant humans do not always have elevated 
serum free fatty acid levels but do appear to maintain higher rates of free fatty acid uptake, 
utilization and subsequent oxidation than lean controls [95]. 
5. The role of cytokines and chronic inflammation in insulin resistance 
Obesity and insulin resistance is associated with chronic systemic inflammation caused by 
activation of the intrinsic immune systems in organs and the macrophages that infiltrate 
them [96]. The most prominent pro-inflammatory mediators involved in this inflammation 
are TNF and IL-6 that originate from: 1) macrophages in adipose tissue and the liver [97], 
2) the adipocytes themselves [97], and, 3) several other cytokine synthesising tissues in the 
body [97-99].  
Elevated free fatty acids may increase pro-inflammatory cytokine expression and synthesis 
since studies inducing acute increases in plasma free fatty acids have observed activation of 
NFB in skeletal muscle in humans [79] and increases hepatic TNF, IL-1 and IL-6 and 
circulating monocyte chemotactic protein-1 (MCP-1) in rats [100, 101]. How elevated fatty 
acid cause NFB activation is unknown but may involve DAG and PKC [102] or the Toll-like 
receptor 4 (TLR-4) [103]. MCP-1 is also known to regulate recruitment of macrophages to 
sites of inflammation and may be involved in the recruitment and differentiation of 
monocytes to macrophages that produce pro-inflammatory cytokines in conditions such as 
obesity and dyslipidaemia [97, 104].  
TNF causes insulin resistance by suppressing IRS-1 associated insulin signalling and 
glucose transport in skeletal muscle while IL-6 activates the phosphatase SHP-2 and Signal 
transducer and activator of transcription 3 (STAT3) causing increased expression of 
suppressor of cytokine signalling 3 (SOCS3) [105, 106]. IL-6 also activates several 
serine/threonine kinases such as JNK, p38 mitogen activated protein kinases and PKC- that 
contribute to reduced insulin sensitivity and glucose metabolism (Figure 4) [107, 108].  
Information relating to the possible role of inflammation in the aetiology of myocardial 
insulin resistance is limited. A recent study however reported that high fat feeding caused 
increased myocardial macrophage infiltration and increased cytokine and SOCS levels in 
cardiomyocytes from these animals [109]. These changes were associated with reduced 
myocardial insulin sensitivity and glucose metabolism.  
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Figure 4. Proposed mechanism for inflammation induced insulin resistance in muscle. Cytokines from 
macrophages and myocytes activate their receptors and associated signalling pathways to increase 
serine (inhibitory) phosphorylation of IRS-1. IL-6 is known to activate the STAT3-SOCS3 pathways 
while TNF activates JNK to phosphorylate IRS-1. 
6. The role of the Renin-Angiotensin System (RAS) in insulin resistance 
The authors [110] and others [111-115] have shown that the systemic and tissue renin-
angiotensin systems (RAS) activity is increased in obesity. The role of increased RAS activity 
in metabolic and cardiovascular disease has been reviewed in detail [29, 116-118].  A key 
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observation linking the RAS system to insulin resistance was made when it became 
apparent that hypertensive patients treated with angiotensin converting enzyme (ACE) 
inhibitors or angiotensin (AT) receptor blockers have a reduced risk of developing insulin 
resistance and type-2 diabetes when compared to patients on other conventional anti-
hypertensive therapy [119, 120]. Subsequent studies have corroborated these observations 
with RAS inhibition improving blood glucose management [121] and lowering risk of type-2 
diabetes [122]. These data provided indirect evidence to suggest that the RAS (and 
particularly over-activation) contributes to insulin resistance and type-2 diabetes. 
Several human and animal studies support a role for RAS over-activity in insulin resistance. 
Genetic abnormalities leading to over-activation of the RAS provides strong evidence for the 
involvement of the RAS in insulin resistance. In infants [123] and adults [124, 125] the DD 
genotype of the ACE I/D polymorphism is associated with glucose intolerance and insulin 
insensitivity. Similarly, AGTT174M polymorphisms are associated with metabolic syndrome 
in aboriginal Canadians [126].  
As mentioned previously, pharmacological blockade of the RAS in clinical trials has 
provided the most compelling evidence for a role for RAS over-activity in metabolic 
abnormalities such as insulin resistance. The use of ACE inhibitors for antihypertensive 
therapy reduces the risk of developing type-2 diabetes by 14% [119]. Studies on animals 
support these observations with RAS inhibition improving insulin sensitivity in rat [127] 
and mice [128]. Genetic deletion of renin [129] or ACE [130] or one of the two AT receptors  
also appears to be effective in preventing or reducing insulin resistance in mice [131, 132]. 
Besides the evidence showing that inhibition of RAS activity may improve insulin 
sensitivity, several studies also provide direct evidence implicating over-activation of the 
RAS in the aetiology of insulin resistance. Chronic angiotensin II infusion causes insulin 
resistance in rats [133, 134] while the TG(mREN2)27 rat which suffers from chronic systemic 
RAS over-activation develops muscle and systemic insulin resistance [135]. The RAS 
induced insulin resistance in these animals is improved by renin inhibition or angiotensin 
receptor blockade [135, 136]. 
The mechanism for angiotensin II (Ang II) induced insulin resistance has received 
significant attention. Ang II adversely affects glucose metabolism and decreases its uptake 
and utilisation by interfering with insulin signalling [137]. In L6 myocytes Ang II suppresses 
insulin induced phosphorylation of the tyrosine residue on IRS-1. This was associated with 
decreased activation of PKB/Akt and GLUT4 translocation to the sarcolemma. These 
changes were all AT1 receptor, NADPH oxidase and NFB dependent [138, 139]. Based on 
these observations it seems likely that Ang II activates NADPH oxidase and increases 
reactive oxygen species (ROS) generation through the angiotensin type 1 (AT1) receptor. 
ROS activate the NFB to increase transcription of cytokines that include TNF and IL-6. 
These cytokines increase SOCS3 expression which inhibits insulin signalling (Figure 5) [140]. 
In rats Ang II also reduces skeletal muscle mitochondrial content (possibly through 
increased ROS generation) which would be expected to reduce muscle glucose utilisation 
[141].  
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Figure 5. Proposed mechanism for renin-angiotensin system over-activation induced insulin resistance. 
Angiotensin II activates NADPH oxidase to generate reactive oxygen species (ROS) which activate the 
translocation of NFB to the nucleus. Here it causes the transcription, synthesis and release  of cytokines 
(TNF and IL-6). The binding of these cytokines to their sarcolemmal receptors induce serine kinases 
and SOC3 which inhibits IRS-1 tyrosine phosphorylation, insulin signalling and GLUT4 translocation.  
Adipose tissue RAS over-activity may also contribute to systemic insulin resistance since 
Ang II from adipose tissue contributes to circulating Ang II levels. This was well 
demonstrated by a study investigating the effect of adipose tissue angiotensinogen (Agt) 
over-expression on systemic glucose tolerance and insulin resistance [142]. The over-
expression of Agt in adipose tissue caused cardiac and skeletal insulin resistance and 
reduced muscle glucose uptake. 
7. The role of adipocytokines in the aetiology of insulin resistance 
Adipocytokines released from adipose tissue perform regulatory functions in energy and 
fluid balance and satiety and have been implicated in conditions such as obesity, 
dyslipidaemia, insulin resistance/diabetes and cardiovascular disease. Besides the two pro-
inflammatory cytokines discussed previously (TNF and IL-6) adipocytes secrete several 
well characterised adipocytokines that include: leptin, adiponectin, and resistin. 
Dysregulation of the synthesis and secretion of these peptides has been associated with, and 
implicated in, the aetiology of metabolic diseases such as insulin resistance and type-2 
diabetes. A possible role for adipokines in the regulation of myocardial metabolism only 
emerged recently [143-145].  
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Leptin is synthesised by white adipose tissue and is involved in appetite control and energy 
expenditure. Although the absence of leptin leads to obesity and insulin resistance, most 
obese patients have elevated leptin levels but do not respond to the appetite suppressing 
and other effects of the peptide [146, 147]. Mutations of the leptin receptor (Ob-R) are 
associated with obesity in the db/db mouse [148] and the Zucker (fa/fa) rat [149] and leptin 
deficiency occurs in obese (ob/ob) mice [150] while the treatment of patients [151, 152] and 
animals [150] with recombinant leptin reduces body weight and improves serum lipid 
levels.  
Serum triglyceride levels and blood glucose handling also improved in women with 
lipodystrophy and leptin deficiency indicating that leptin may alter lipid metabolism and 
prevent lipotoxicity [153]. Animal studies demonstrate that leptin promotes lipid oxidation. 
In rat adipocytes leptin reduces insulin’s’ lipogenic effect by: 1) inhibiting insulin binding to 
its receptor [154], 2)  increasing adipose and non-adipose tissue -oxidation, and, 3) 
decreasing adipose tissue triglyceride content without elevating circulating free fatty acids 
(Figure 6) [74].  This reduction in serum fatty acid levels will also counter the effect of 
insulin on lipogenesis [74, 154].  
 
Figure 6. A simplified illustration to demonstrate the effects of adipocytokines on tissue insulin 
sensitivity and inflammation.  
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There is a strong association between leptin deficiency/resistance and lipotoxicity [155]. 
The lipid lowering effects of leptin in heart muscle was demonstrated in a study where 24 
hour high fat feeding of mice was associated with cardiac lipid accumulation in animals 
with low leptin levels but not those with high plasma leptin levels [156]. Leptin 
administration decreases cardiac muscle lipotoxicity in a subsequent study by this group 
[157]. 
Leptin administration to the perfusate of isolated rat hearts perfused with palmitate and 
glucose significantly increased fatty acid oxidation and reduced intramyocardial triglyceride 
content without increasing cardiac work. This was accompanied by increased myocardial 
oxygen consumption and reduced cardiac efficiency [143].  The significance of leptin in 
metabolism is further highlighted in genetic models such as the leptin deficient ob/ob mouse 
and the leptin resistant db/db mouse that has a loss-of-function mutation on the leptin 
receptor. These animals are obese, insulin resistant and display excess intramyocardial lipid 
accumulation. They are also more prone to increased cardiomyocyte apoptosis and cardiac 
dysfunction than their control littermates [158-162]. 
Circulating adiponectin levels are reduced in obesity, insulin resistance and diabetes and 
correlate with the extent of insulin resistance and hyperinsulinaemia [163-165]. It is 
synthesised by adipocytes, skeletal muscle, heart muscle and endothelial cells [166] and is a 
key adipocytokine in the regulation of metabolism. It is considered to be an anti-diabetic, 
anti-inflammatory and anti-atherogenic agent with adiponectin deficient animals becoming 
glucose intolerant, insulin resistance and hyperleptinaemic [167, 168]. Studies utilising 
adiponectin replacement therapy have demonstrated its ability to decrease dyslipidaemia 
[169] and improve insulin sensitivity (Figure 6) [170-172]. 
Adiponectin acts via phosphorylation of 5'adenosine monophosphate-activated protein 
kinase (AMPK) to influence insulin sensitivity and fatty acid and glucose utilisation [172, 
173]. Its action is mediated through the AdipoR1 and AdipoR2 receptors [170] that are both 
expressed in cardiac tissue [174]. Receptor activation is associated with modulation of 
AMPK, PI3K, p38 MAP kinase and extracellular signal-regulated kinase (Erk) 1/2 MAP 
kinase [175-177].  
Resistin is secreted from white adipose tissue but is also expressed in other tissues [178]. It 
was given its name because it was originally shown to counter the effects of insulin by 
suppressing insulin signalling [179]. Over-expression of resistin is associated with 
dyslipidaemia and insulin resistance [180, 181] and inhibition of glucose uptake in 
cardiomyocytes [182]. In humans plasma resistin levels are closely correlated to insulin 
resistance irrespective of body weight [183]. However, these observations are not supported 
by two animal studies that found that resistin levels were not a good predictor of insulin 
resistance when corrected for body mass index (BMI) [184, 185]. In both high fat diet and 
genetic mutation induced obesity, resistin levels were closely associated with body weight 
with obese animals having significantly elevated resistin levels [179]. The exact role of 
resistin in insulin resistance is however poorly understood and unresolved. 
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8. Effects of myocardial insulin resistance on myocardial metabolism, 
mechanical function and tolerance to ischaemia and reperfusion 
The heart utilises glucose, fatty acids and lactate as fuels for the production of ATP. Cardiac 
metabolism is under the control of several hormones with insulin being a key regulator of 
glucose, fatty acid and lactate metabolism. Changes in myocardial insulin sensitivity disrupt 
the hearts’ normal substrate metabolism and potentially decrease mechanical function and 
myocardial tolerance to ischaemia/reperfusion.   
8.1. Myocardial metabolism 
The heart is a dynamic organ, constantly requiring energy in the form of ATP in order to 
meet its homeostatic and contractile demands. This is achieved through a constant supply of 
oxidizable substrates from the circulation. The most important substrates utilized by the 
heart are: fatty acids, glucose and lactate. Although the adult heart is capable of oxidizing a 
variety of substrates, the majority of ATP (60-70%) generated by the heart originates from 
the oxidation of fatty acids [186, 187]. However, in the presence of elevated glucose and 
insulin levels as occurs immediately following a meal, 60-70% of ATP may be derived from 
glucose metabolism [188]. 
Circulating fatty acids are taken up by the heart either in their free form (as free fatty acids 
(FFAs)) bound to albumin, or they can be released from the triglyceride component of 
chylomicrons or very-low-density-lipoproteins (VLDL) [189]. The concentration of fatty 
acids present in blood greatly dictates their uptake and metabolism by the heart [190]. 
Under normal physiological conditions, long chain fatty acids (LCFAs) are the principal 
fatty acids oxidized by the heart [191]. The entry of LCFAs across the sarcolemma into the 
cytoplasm of the cardiomyocyte occurs though passive diffusion or membrane protein 
mediated transport, the latter accounting for the majority of fatty acid translocation to the 
cytosol [192]. This membrane protein mediated transport is facilitated by fatty acid 
translocase (FAT)/CD36, plasma membrane fatty acid binding protein (FABPpm) and fatty 
acid transport protein (FATP) [192]. Once inside the cell, non-esterified LCFAs are 
transported via cytoplasmic heart-type FABPs through the cytoplasm to the location where 
they will be utilized [193-195]. LCFAs are then esterified by acyl-CoA synthetase to form 
long chain fatty acyl-CoA’s (LCFA-CoA) [55]. LCFA-CoAs can be stored in intracellular 
lipid pools where they can be converted to additional lipid intermediates (triglycerides, 
diacylglycerol (DAG) or ceramide), or are transported to the mitochondria where they 
undergo β-oxidation.  
Glucose enters the cardiomyocyte through either the basal uptake glucose transporter, 
GLUT1, or via the insulin dependent glucose transporter, GLUT4 [196]. GLUT4 is stored in 
cytoplasmic vesicles which are recruited to the sarcolemma in response to insulin 
stimulation or cardiac contraction. Glucose itself can also induce GLUT4 translocation with 
this and insulin stimulated translocation determining the glucose flux rate into the 
cardiomyocyte [197]. Inside the cell hexokinase converts glucose to glucose-6-phosphate 
which can be stored as glycogen (after conversion by glycogen synthase) or it can undergo 
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glycolysis to yield pyruvate and ATP.  During adequate myocardial oxygen availability 
pyruvate is transported into the mitochondria via a mitochondrial monocarboxylate 
transporter [198] and subsequently oxidized by pyruvate dehydrogenase (PDH) to produce 
acetyl-CoA (reviewed by Stanley et al. [199]). During anaerobic conditions as occurs during 
myocardial ischaemia, pyruvate may be converted to lactate. 
The rate of glucose oxidation is also influenced by fatty acid β-oxidation rates since 
hexokinase, PFK and PDH activity are all inhibited by various  products of fatty acid 
metabolism (for a review see Hue and Taegtmeyer [200]). There is a delicate interplay in the 
utilisation of these two myocardial substrates which is intricately related to their circulating 
levels. The common endpoint where glucose and fatty acid metabolism converge is the 
production of acetyl-CoA which enters the tricarboxylic acid/Krebs cycle where it is used to 
generate ATP during oxidative phosphorylation [187, 201]. Alternatively the acetyl-CoA can 
be utilised in non-oxidative pathways for the production of triglycerides, DAG and 
ceramide. 
8.2. Impact of myocardial insulin resistance on myocardial metabolism 
The early onset of insulin resistance in obesity may be a physiological response to increased 
lipid availability leading to increased lipid utilisation and a reciprocal reduction in glucose 
metabolism. Chronic dysregulation of glucose uptake and metabolism by dyslipidaemia and 
inflammation may however induce pathological changes in cardiac metabolism that 
compromise cardiac morphology and mechanical function.  
High fat feeding of C57BL/6 mice induces myocardial insulin resistance within 10 days. This 
insulin resistance was associated with reduced myocardial glucose uptake, PKB/Akt activity 
and GLUT4 protein levels and preceded and occurred independently of systemic insulin 
resistance [202]. With myocardial insulin resistance, fatty acid oxidation rates are normal or 
elevated, while glucose oxidation rates are normally reduced both in the presence or 
absence of insulin stimulation [5, 44, 45, 203-205]. Although a limited number of studies 
have reported similar myocardial fatty acid and glucose oxidation rates in obese, insulin 
resistant animals when compared to lean controls, they have all found that insulin stimulated 
myocardial glycolytic flux rates remain suppressed with insulin resistance [89, 206]. In humans 
similar increases in myocardial fatty acid metabolism were reported in obese men and women. 
Gender however also played and important role in determining the impact of obesity of 
glucose and fatty acid uptake and utilization [207]. Women were less prone to obesity induced 
dysregulation of myocardial metabolism than their obese male counterparts. These gender 
based differences in myocardial metabolism in response to obesity may translate to differences 
in the development of obesity-related cardiovascular diseases. 
8.3. Effect of insulin resistance on cardiac mechanical function 
Increased lipid uptake and oxidation as seen with insulin resistance potentially leads to 
cellular lipid intermediate accumulation, excessive mitochondrial or peroxisomal ROS 
generation and functional derangement in the 
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study showing that cardiac specific PPAR over-expression which increases cardiac lipid 
oxidation causes metabolic derangements and leads to adverse structural and function 
changes in the heart [208]   
Pre-diabetic (insulin resistant) obese Zucker rats display cardiac dysfunction [47]. These 
observations were corroborated in obese insulin resistant mice (ob/ob and db/db) that had 
increased myocardial lipid oxidation rates, decreased glucose oxidation rates and decreased 
cardiac efficiency. These changes were also associated with systolic dysfunction when 
compared to lean insulin sensitive littermates [45].  
Although genetic models of obesity do not accurately resemble the phenotype of human 
obesity, the recent development of a number of models of diet-induced  obesity have 
contributed to a better understanding of the impact of obesity and insulin resistance on 
myocardial function. High fat feeding induced insulin resistance in C57BL/6 mice also 
causes cardiac remodelling and systolic dysfunction [202]. The authors and other research 
groups have however also shown that rodent models of diet-induced obesity with insulin 
resistance have either normal [90, 203, 205, 209, 210] or compromised [110, 203, 204, 211, 212] 
cardiac mechanical function. It is currently not possible to conclusively attribute the cardiac 
dysfunction reported in these studies to myocardial insulin resistance since there are several 
studies that have reported normal cardiac function in animal models with insulin resistance 
[90, 203, 205, 209, 210].  
Reduced cardiac efficiency possibly contributes to cardiac dysfunction in obesity, insulin 
resistance and diabetes [44, 45, 213]. Animals [44, 45, 162, 213] and humans [95] that are 
obese and insulin resistant or diabetic have increased myocardial oxygen consumption 
which reflects a decreased cardiac efficiency as determined by the myocardial work to 
myocardial oxygen consumption ratio [214]. Mitochondria isolated from obese insulin 
resistant mice have reduced oxidative capacity, and display fatty acid induced uncoupling 
of mitochondrial oxygen consumption and ATP production which is evident from the 
reduced ATP-to-O ratios [162, 213]. This data from human and rodent studies also implicate 
impaired mitochondrial energetics in the cardiac dysfunction associated with obesity and 
insulin resistance. Recent epidemiological evidence points to an important mediatory role 
for insulin resistance in the development of obesity related congestive heart failure [215]. 
8.4. Effect of dyslipidaemia and insulin resistance on myocardial tolerance to 
ischaemia/reperfusion 
A key feature of myocardial ischaemia is the reduced oxygen and substrate availability that 
results in lower mitochondrial oxidative phosphorylation rates. Ischaemia essentially 
disrupts the tightly coupled ATP breakdown and re-synthesis equilibrium that exists during 
normoxia and leads to an ATP deficit. Cellular ATP becomes depleted with the extent of this 
depletion being dependent on the duration and severity of ischaemia [216].  
Although oxidative metabolism is reduced during ischaemia, reperfusion after ischaemia is 
associated with an initial increase in glycolytic flux rate which quickly declines to normal 
levels [217]. Despite glycolysis only accountings for a small amount of the total ATP 
 
Insulin Resistance 206 
production under aerobic conditions, glycolytically generated ATP becomes invaluable in 
the maintenance of cellular ion pump function and ion homeostasis and the reduction of 
myocardial damage during mild ischaemia [218]. While glycolytically produced ATP may 
aid in maintaining ion homeostasis during ischaemia, it is insufficient for the maintenance of 
myocardial contractile function [218]. Under conditions of severe ischaemia in the absence of a 
glucose and oxygen, myocardial glycogen stores undergoing glycolysis do not only contribute 
to the ATP synthesised, but greatly increase cytosolic proton accumulation and a decline in 
intracellular pH [219]. Despite its potential adverse effect on pH, elevated glycogen levels at 
the onset of myocardial ischaemia may be important in maintaining tissue ATP levels since it 
has been associated with improved functional recovery after ischaemia [220].  
Despite myocardial ischaemia decreasing mitochondrial substrate oxidation, fatty acid 
oxidation predominates during ischaemia and subsequent early reperfusion [221].  During 
early ischaemia there is a transient increase in anaerobic glycolysis while glucose oxidation 
decreases [199, 221-224]. Under these conditions normal or increased glucose uptake (under 
the influence of insulin) may be important for the delivery of glycolytic ATP to maintain ion 
homeostasis. Hearts from animal models of obesity and insulin resistance [211], isolated 
insulin resistance [225] and diabetes [226] have a reduced tolerance to ischaemia and 
reperfusion and suffer more severe ischaemia/reperfusion injury. Myocardial insulin 
resistance potentially decreases myocardial tolerance to ischaemia by decreasing glucose 
uptake, glycogen synthesis and glycolysis which all play a critical role in the delivery of 
ATP for cellular homeostasis in the ischaemic/reperfused heart.  
Although fatty acids are predominantly oxidized by the ischaemic heart, the preference for 
fatty acid oxidation as occurs under dyslipidaemic conditions also has adverse effects on the 
ischaemic and reperfused heart. The mitochondrion generates 12% less ATP per oxygen 
molecule through the oxidation of fatty acids compared to glucose oxidation during 
normoxia [187]. Increased fatty acid oxidation consequently reduces cardiac efficiency 
during ischaemia and subsequent reperfusion. During reperfusion the glycolytic flux rate 
exceeds glucose oxidation rates which remains suppressed due to increased fatty acid 
oxidation during reperfusion [224, 227]. This fatty acid induced uncoupling of glucose 
oxidation from glycolysis results in an accumulation of hydrogen ions which can damage 
the heart and affect post ischaemic function [199, 228-230]. These detrimental effects of 
increased fatty acid -oxidation during both ischaemia and reperfusion would be expected 
to be pronounced in dyslipidaemia (as occurs in obesity and high fructose feeding) and 
insulin resistance and exacerbate ischaemic injury.  
Pharmacological inhibition of myocardial fatty acid oxidation prior to the onset of, or during 
reperfusion results in increased glucose oxidation and improved cardiac functional recovery 
following the ischaemic episode [224, 227]. Hearts from prediabetic obese Zucker rats have 
reduced GLUT4 expression, reduced glucose uptake and larger reductions in tissue ATP 
levels during low-flow ischaemia. These changes are associated with poorer post-ischaemic 
functional recoveries when compared to their lean control littermates [231]. Treating these 
rats with rosiglitazone (the insulin sensitizer) normalized myocardial total GLUT4 protein 
expression, myocardial ischaemic substrate metabolism and improved reperfusion 
functional recovery. 
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8.5. The effect of insulin resistance on myocardial pro-survival signalling and 
ischaemic tolerance 
The ability of the heart to withstand injury during ischaemia and reperfusion is not only 
dependent on myocardial metabolism but also upon the expression and functionality of its 
intrinsic pro-survival signalling pathways. Investigations into cardioprotection with 
preconditioning and postconditioning has revealed common signalling elements that 
transduce protective stimuli and converge on mitochondrial targets [232-234]. These stimuli 
recruit paths comprising cell surface G-protein coupled receptors (GPCRs), signalling kinase 
networks (e.g. PI3K-Akt-eNOS, Erk1/2, PKC, p38-MAPK, Glycogen synthase kinase 3 beta 
(GSK3)) that have been dubbed the Reperfusion Injury Salvage Kinases (RISKs), and 
mitochondrial components that may represent end-effectors. These end-effectors include KATP 
channels and the mitochondrial permeability transition pore - mPTP (Figure. 7). Central to the 
RISK pathways is protein kinase B (PKB)/Akt which is not only key to myocardial insulin 
signalling  [188] and physiological hypertrophy/remodelling [235] but is also considered a pro-
survival/anti-apoptotic kinase in the context of myocardial ischaemia/reperfusion. 
 
Figure 7. An illustration demonstrating the pivotal role of PKB/Akt in the RISK and insulin signalling 
pathways and the possible impact of dyslipidaemia and insulin resistance on these signalling pathways. 
Broken line represents the proposed mechanism linking insulin resistance with PKB/Akt 
inhibition/inactivation and Reperfusion Injury Salvage Kinase (RISK) pathway dysfunction. 
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Insulin regulates cardiac metabolism, growth and mitogen-activated protein kinase (MAPK) 
pathways through pivotal PKB/Akt. Dyslipidaemia induced insulin resistance which is 
characterized by PI3K/Akt dysregulation possibly also negatively influences the 
functionality of the RISK pathway in the heart during ischaemia/reperfusion.  
Early experimental evidence has emerged to support a role for obesity with insulin 
resistance in RISK pathway dysfunction. Wagner and co-workers [236] have shown loss of 
preconditioning in a rat model of established metabolic syndrome. In the leptin-deficient 
(ob/ob) mouse cardiac benefit from postconditioning is impaired [237], while there is also 
evidence of failed preconditioning in obese insulin-resistant rats [238]. Failure of a variety of 
cardioprotective interventions involving multiple and varied triggers, implicates dysfunction 
of the signalling paths of the RISK pathway that are common to these interventions. This is 
also supported by the recent findings of Bouhidel and co-workers [237] who reported 
impaired phosphorylation of Akt, Erk1/2 and p70S6K1 in ob/ob mice while others [236] 
presented evidence of impaired Erk1/2 activation and failure to phosphorylate and inactivate 
GSK3β. Ineffective protection in obese insulin resistance rats is also associated with impaired 
activation of the mitochondrial KATP channel [238]. All early indications suggest that distinct 
changes in intrinsic cardioprotective signalling occur in myocardial insulin resistance.  
9. Interventions and therapy for the treatment of insulin resistance 
Compelling scientific evidence indicates that obesity and/or lipogenic diets that lead to 
dyslipidaemia promote insulin resistance. Besides the dyslipidaemia, abnormal RAS activity 
and perturbations in adipocytokine levels also contribute to tissue insulin insensitivity. The 
primary goal of therapy for the treatment of insulin resistance should therefore be to 
prevent or reduce obesity (adipose tissue expansion) and dyslipidaemia. In addition to 
normalising circulating lipid levels, weight loss would normalise adipose tissue content and 
its associated pro-inflammatory cytokine and adipocytokine levels and ultimately improve 
insulin resistance.  Since there is a direct correlation between obesity and RAS over-
activation, weight loss and/or RAS inhibition has the potential to attenuate the adverse 
effects of abnormal RAS activity on tissue insulin signalling.   
9.1. Lifestyle changes:  Physical activity and diet 
Maintaining normal body weight or reducing body weight in overweight patients is the 
preferred approach for the prevention or treatment of the underlying causes of insulin 
resistance. Regular physical activity aimed at balancing caloric intake with caloric 
expenditure is recommended to maintain body weight. To reduce body weight caloric intake 
should be reduced and caloric expenditure increased until the desired body weight has been 
achieved. Current recommendations are to do 30 minutes moderate intensity exercise daily in 
order to maintain normal body weight and reduce the risk of developing medical conditions 
such as cancer, insulin resistance, diabetes and cardiovascular disease [239].  
In addition to regular exercise to maintain normal body weight or promote weight loss, 
individuals with a genetic predisposition to obesity, insulin resistance and diabetes should 
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carefully manage their diet and reduce their intake of refined sugars, trans- and saturated 
fats and cholesterol and increase their consumption of grains, and fruit and vegetables [240]. 
Based on recent evidence provided by studies investigating the potential role of fructose in 
dyslipidaemia and metabolic diseases [24, 27, 41], it would also be prudent to avoid the 
overconsumption of fructose rich foods and beverages.  
The larger the BMI loss achieved through exercise and/or dietary restriction, the larger the 
metabolic improvements that are achieved. Weight loss improves lipid profiles and blood 
glucose levels in metabolic syndrome patients [241] with a weight loss of more than 10% 
reversing metabolic disorders in two-thirds of metabolic syndrome patients studied [242]. 
These patients no longer met the criteria for metabolic syndrome. Lifestyle interventions 
also decreases the progression from insulin resistance to type-2 diabetes. In the US Diabetes 
Prevention Program, interventions aimed at reducing body weight by 7% succeeded in 
preventing progression from insulin resistance to type- 2 diabetes by 58% [243]. In this study 
38% of the patients with metabolic syndrome at entry into the study had a reversal of 
metabolic syndrome with body weight loss.  
9.2. Drug therapy that improves insulin sensitivity 
Although lifestyle changes should remain the therapy of choice for the reduction of body 
weight and normalisation of metabolic disorders, not all patients respond to lifestyle 
changes to the same extent. In many cases lifestyle changes fail to achieve the intended 
objective of adequate weight loss. Under these circumstances pharmacological interventions 
have to be considered. Several drugs have been developed to improve lipid profiles and 
insulin sensitivity/action but have been disappointing and have in some cases had adverse 
side effects.  
9.2.1. Lipid lowering drugs  
Dyslipidaemia which presents as elevated circulating triglycerides and LDL-cholesterol and 
low HDL-cholesterol can be treated with statins (3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors) that reduce levels of all forms of Apo B containing 
lipoproteins [244-247]. These drugs reduce the conversion of acetyl-CoA to mevalonate and 
the eventual synthesis of cholesterol in the liver by blocking HMG-CoA reductase. There are 
several studies that have demonstrated that statins (simvastatin and atorvastatin) improve 
plasma triglyceride and glycosylated haemoglobin in non insulin dependent diabetics [246]. 
Fluvastatin also improved lipid profiles and insulin resistance in nondiabetic dyslipidaemic 
patients. These researchers however concluded that the insulin sensitising effects of 
fluvastatin were not related to its triglyceride lowering effects [247].   
Another class of lipid lowering drug that has achieved satisfactory results is the fibrates that 
activate peroxisome proliferator-activated receptor (PPARs) and facilitate lipid metabolism. In 
humans, fibrates lower circulating triglyceride and LDL-C levels [248, 249] and elevate HDL-C 
levels [249]. PPARα agonists possibly improve lipid profiles by increasing the synthesis of 
both apolipoprotein A-I [248] and A-II [250] which would assist in increasing HDL-cholesterol 
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while reducing apolipoprotein B which is a major lipoprotein constituent of LDL-cholesterol. 
PPARα agonists also increase hepatic mitochondrial β-oxidation which reduces hepatic free 
fatty acids that are an essential component of VLDL and LDL-cholesterol.  
Since PPARα agonists have repeatedly been demonstrated to have both systemic and tissue 
specific insulin sensitizing effects [251-254] their potential for the treatment of insulin 
resistance and diabetes is encouraging. The insulin sensitising effects of the fibrates 
probably relate to their lipid lowering effects since a PPARα agonist significantly increases 
hepatic and skeletal muscle insulin receptor and IRS-1 tyrosine phosphorylation, while 
increasing IRS-associated PI3K activity in obese (ob/ob) mice [252]. These insulin sensitising 
effects were accompanied by reduced hepatic, skeletal muscle [252] and heart muscle [255] 
lipid accumulation.   
Combination therapy using statins and fibrates has been an attractive possibility but the 
results have been disappointing. The fibrate gemfibrozil in combination with statins has 
been associated with increased risk of myopathy [256]. It has however been proposed that 
the adverse effects of gemfibrozil and statin combination therapy may be due to a 
pharmacological interaction between  these two drugs and that other fenofibrates may be 
more suitable for combination therapy with statins [257]. 
9.2.2. Insulin sensitizers 
The two most promising insulin sensitizers are metformin and the glitazones. Metformin 
decreases hepatic gluconeogenesis and triglyceride production which in turn enhances 
insulin sensitivity [258]. Metformin reduced the progression of insulin resistance (pre-
diabetic) to type-2 diabetes in the Diabetes Prevention Program [243].  
Thiazolidinediones (TZDs) are PPAR agonists that regulate insulin sensitivity in the liver, 
muscle and adipose tissue by increasing fatty acid oxidation and decreasing fatty acid 
synthesis [258]. TZDs are also believed to have anti-inflammatory effects. Pioglitazone was 
used in the ACT-NOW study in which it improved HDL-cholesterol and triglyceride levels 
and reduced the incidence of type-2 diabetes by 78% in prediabetic patients followed up over 2 
years [259]. The Pioglitazone In Prevention Of Diabetes (PIPOD) study demonstrated that 
pioglitazone reduced the incidence of diabetes in premenopausal women [260]. It similarly 
improves insulin sensitivity and reduces both blood FFA and triglycerides levels in obese non-
diabetic patients [261]. The usefulness of pioglitazone for the management of insulin 
sensitivity is however limited since it promotes fluid retention which increases risk of heart 
failure in certain patient populations with cardiovascular disease. In the diabetes reduction 
assessment with ramipril and rosiglitazone medication (DREAM) trial, rosiglitazone showed 
potential in preventing diabetes but appeared to increase the risk of heart failure [262]. 
9.2.3. RAS inhibitors or AT receptor blockers 
Obesity and high fat feeding increases both systemic and adipose tissue RAS activity [110, 
112-115]. As discussed previously in this chapter, the most compelling evidence for a role 
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for the RAS in the aetiology of insulin resistance comes from studies using ACE inhibitors 
and AT receptor antagonists to control blood pressure. Both these therapies are associated 
with reduced risk of developing insulin resistance and type-2 diabetes in patients [119, 122, 
263-266] and in rodent models of obesity and insulin resistance [127, 128]. Although these 
antihypertensives are not prescribed for the treatment of abnormal RAS activity, they 
potentially improve insulin sensitivity in a patient population that is at high risk of 
cardiovascular disease due to their hypertension.     
9.2.4. Anti-inflammatory therapy  
Several lines of evidence implicate chronic inflammation in the aetiology of insulin 
resistance. Obesity is associated with elevated circulating cytokines and C-reactive protein 
which can be normalised by weight loss [267]. Although no drugs are currently available to 
treat chronic systemic inflammation, the use of lipid lowering drugs have been associated 
with reduced C-reactive protein levels in patients [267-269]. These drugs are not prescribed 
to specifically reduce inflammation but may contribute to improved insulin sensitivity by 
improving dyslipidaemia and decreasing its stimulation of -oxidation and ROS generation. 
Increase ROS generation potentially increase cytokine synthesis and release in certain 
organs (Figure 2).  
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